CRA advanced analytics was hired by a pharmaceutical company to assess the impact of Covid-19 on the forecast of their pulmonology product in the US. Using the client’s geographical-level internal sales data, combined with publicly available coronavirus metrics, we were able estimate the trend to their product demand, segmented by state-level Covid-19 severity. The team’s findings were presented to the company’s leadership and board of investors, where the analysis was praised for its technical merit and sophistication in providing data-driven guidance surrounding the level of potential risk to their business.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...